About Oral Cancer Foundation News Team - A

This author has not yet filled in any details.
So far Oral Cancer Foundation News Team - A has created 2444 blog entries.

Researchers and drug companies are ganging up for a new push against cancer

Source: www.economist.com Author: staff “There is no treatment.” This is the conclusion of an Egyptian papyrus, written around 3000BC, that is the oldest known description of the scourge that is now called “cancer”. And so, more or less, it remained until the 20th century, for merely excising a tumour by surgery rarely eliminates it. Only when doctors worked out how to back up the surgeon’s knife with drugs and radiation did cancer begin to succumb to treatment—albeit, to start with, in a pretty crude fashion. Now, however, that crudeness is rapidly giving way to sophistication, as a new wave of cancer treatments comes to market. In 2012 more than 500 potential cancer drugs were under investigation, according to a survey by IMS Health, an American research group—over five times as many as were being developed in the next biggest category, diabetes. Three trends are helping to fill this cancer-drug cornucopia. One is the increase in demand as people live longer, and thus become more likely to develop cancer. According to the World Health Organisation, there were 14m new cases of cancer around the world in 2012. In 2030 there will be nearly 22m. The second trend is the rising price of cancer drugs, particularly in America, the biggest market. More expensive drugs increase profitability. The third is a rapid expansion of scientific knowledge about cancer, the result of both the plummeting cost of genetic sequencing (see chart) and a better understanding of how to recruit the immune system to attack [...]

2014-01-05T13:21:25-07:00January, 2014|Oral Cancer News|
Read More

Surgery beats chemotherapy for tongue cancer, U-M study finds

Source: www.eurekalert.org Author: press release Patients with tongue cancer who started their treatment with a course of chemotherapy fared significantly worse than patients who received surgery first, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. This is contrary to protocols for larynx cancer, in which a single dose of chemotherapy helps determine which patients fare better with chemotherapy and radiation and which patients should elect for surgery. In larynx cancer, this approach, which was pioneered and extensively researched at U-M, has led to better patient survival and functional outcomes. But this new study, which appears in JAMA Otolaryngology Head and Neck Surgery, describes a clear failure. "To a young person with tongue cancer, chemotherapy may sound like a better option than surgery with extensive reconstruction. But patients with oral cavity cancer can't tolerate induction chemotherapy as well as they can handle surgery with follow-up radiation. Our techniques of reconstruction are advanced and offer patients better survival and functional outcomes," says study author Douglas Chepeha, M.D., MSPH, professor of otolaryngology – head and neck surgery at the University of Michigan Medical School. The study enrolled 19 people with advanced oral cavity cancer. Patients received an initial dose of chemotherapy, called induction chemotherapy. Those whose cancer shrunk by half went on to receive additional chemotherapy combined with radiation treatment. Those whose cancer did not respond well had surgery followed by radiation. Enrollment in the trial was stopped early because results were so poor. Ten of [...]

2013-12-30T06:42:46-07:00December, 2013|Oral Cancer News|
Read More

Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients

Source: 7thspace.com Author: staff Introduction: Circulating microRNAs (miRNAs) are easily accessible and have already proven to be useful as prognostic markers in cancer patients. However, their origin and function in the circulation is still under discussion. In the present study we analyzed changes in the miRNAs in blood plasma of head and neck squamous cell carcinoma (HNSCC) patients in response to radiochemotherapy and compared them to the changes in a cell culture model of primary HNSCC cells undergoing simulated anti-cancer therapy.Materials and methods: MiRNA-profiles were analyzed by qRT-PCR arrays in paired blood plasma samples of HNSCC patients before therapy and after two days of treatment. Candidate miRNAs were validated by single qRT-PCR assays. An in vitro radiochemotherapy model using primary HNSCC cell cultures was established to test the possible tumor origin of the circulating miRNAs. Microarray analysis was performed on primary HNSCC cell cultures followed by validation of deregulated miRNAs via qRT-PCR. Results: Unsupervised clustering of the expression profiles using the six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p) significantly (p = 0.012) separated plasma samples collected prior to treatment from plasma samples collected after two days of radiochemotherapy. MiRNA profiling of primary HNSCC cell cultures treated in vitro with radiochemotherapy revealed differentially expressed miRNAs that were also observed to be therapy-responsive in blood plasma of the patients (miR-425-5p, miR-21-5p, miR-106b-5p, miR-93-5p) and are therefore likely to stem from the tumor. Of these candidate marker miRNAs we were able to validate by qRT-PCR a deregulation of eight plasma [...]

2013-12-30T06:35:28-07:00December, 2013|Oral Cancer News|
Read More

Lymphoseek designated fast track status in head and neck cancer

Source: www.empr.com Author: press release Navidea announced that the FDA has granted Fast Track designation to Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer. Lymphoseek Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. Lymposeek Injection was evaluated in a prospective, open-label, multicenter, within-patient study (NEO3-06). It was designed to identify sentinel lymph nodes (SLNs) and determine the false negative rate (FNR) associated with Lymphoseek-identified SLNs relative to the pathological status of non-SLNs in head and neck and intraoral squamous cell carcinoma. The primary endpoint for the NEO3-06 trial was based on the number of subjects with pathology-positive lymph nodes following a multiple level lymph node dissection. A minimum of 38 subjects whose lymph nodes contained pathology-confirmed disease was required. Thirty nine subjects out of over 80 subjects enrolled were determined to have pathology-positive lymph nodes. Navidea intends to file the supplemental New Drug Application (sNDA) for Lymphoseek before the end of 2013. Lymphoseek is already approved for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma.

2013-12-11T04:54:14-07:00December, 2013|Oral Cancer News|
Read More

Head and neck cancer patients improves with hyperfractioned radiotherapy

Source: health-beauty-2468.blogspot.com Author: Kris Borowczyk Compared with the standard radiation therapy, intensified form of radiotherapy proves to be more effective in improving the survival chances of people with head and neck cancer. This is the result of studies conducted by the ECC2013 or European Cancer Congress 2013. About 11,000 patients were subject to altered fractionation radiotherapy and fractionation radiotherapy. The AFRT group showed an 8% reduction in risks for death while the other group showed nine percent in decrease. Radiation oncologist Dr. Pirre Blanchard plans to tell the congress that despite the fact that CRT or concomitant chemo radiation and chemotherapy in general is considered the standard treatment for cancer, AFRT should still be considered if patients want more intensified intervention. He said, “The CRT is not feasible because of other pre-existing conditions such as cardiac and renal diseases.” AFRT is a radiotherapy treatment intensified to be given in different schedules. It is associated with some acute side effects but not those late side effects caused by SFRT.

2013-12-09T14:43:55-07:00December, 2013|Oral Cancer News|
Read More

Certain genetic alterations may explain head and neck cancer survival disparities

Source: www.sciencecodex.com Author: staff Certain genetic alterations to the PAX gene family may be responsible for survival disparities seen between African-American and non-Latino white men with head and neck cancer, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9. "During the last 30 years, the overall five-year relative survival rates for head and neck squamous cell carcinoma (HNSCC) have increased, but despite that, the gap in overall survival rates between non-Latino white patients and African-American patients has remained unchanged," said Rafael Guerrero-Preston, Dr.P.H., assistant professor at Johns Hopkins University in Baltimore, Md. "This disparity may be due to differences in genetic and epigenetic alterations among African-American patients." To test this theory, Guerrero-Preston and colleagues performed a two-stage epigenomic study. In the stage-one discovery phase, the researchers used next-generation sequencing and array-based technologies to evaluate 107 HNSCC samples. In the stage-two validation phase, they validated the findings of the discovery phase and evaluated their effect on survival rates in 279 patient samples from The Cancer Genome Atlas project. "Our results highlight the differential genomic and epigenomic alterations in PAX, NOTCH, and TP53 pathways between African-American and non-Latino white HNSCC patients, which underlie the complex biology of morphologically similar tumors and explain HNSCC survival disparities," Guerrero-Preston said. "If further validated in larger cohorts, these discoveries could be used to develop genomic and epigenomic panels that will enable more treatment options, a reduction in treatment [...]

2013-12-09T14:38:31-07:00December, 2013|Oral Cancer News|
Read More

Genetic markings could spot cancer before it develops

Source: www.thealmagest.com Author: press release Unique DNA markings on certain genes may “predict” the risk of developing head and neck cancer, according to new research led by Queen Mary University of London. The findings, published in the journal Cancer, raise the potential for the development of non-invasive tests which could pick up these tell-tale signs of early cancer initiation. Head and neck cancers are cancers that develop anywhere in the head and neck, including mouth cancer and throat cancer. About 16,000 people in the UK are diagnosed with head and neck cancer every year*. In this study scientists analysed clinical specimens of malignant tissue from 93 cancer patients from Norway and the UK. These were compared with either tissue donated by healthy individuals undergoing wisdom tooth extractions, or with non-cancerous tissue from the same patients. They were trying to identify whether there were any epigenetic changes in the cancerous cells which were not seen in the healthy cells. Epigenetics is the study of changes in gene expression caused by mechanisms other than changes in the underlying DNA sequence. Not all genes are active all the time and there are many ways that gene expression is controlled. DNA methylation marks act as ‘switches’, either turning genes on or off. Abnormal DNA methylation is known to precede cancer initiation. Lead researcher Dr Muy Teck-Teh, from the Institute of Dentistry at Queen Mary, said: “In this study we have identified four genes which were either over or under-expressed in head and neck cancer. [...]

2013-12-09T07:49:48-07:00December, 2013|Oral Cancer News|
Read More

Swallowing exercises preserve function in head and neck cancer patients receiving radiation

Source: http://www.newsfix.ca/ Author: staff A study at UCLA’s Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises — called a “swallow preservation protocol” — during therapy. The study, conducted from 2007 to 2012, was led by Dr. Marilene Wang, a member of the Jonsson Cancer Center and professor-in-residence in the department of head and neck surgery at UCLA’s David Geffen School of Medicine. The study was published online by the journal Otolaryngology–Head and Neck Surgery, and will appear later in the journal’s print edition. Surgery and radiation have been the traditional treatments for head and neck cancer, but with the advent of improved and targeted chemotherapy, many types of this disease are treated with chemotherapy and radiation, (chemoradiation) in the hope of preserving the tissue and structure. But, even when tissue and structure are preserved, patients do not always retain their ability to swallow naturally and normally. Most patients who receive chemoradiation have significant side effects during treatment and for a long time after recovery. Difficulty swallowing (dysphagia) is one of the most common unwanted side effects of radiation and chemoradiation, and is one of the main predictors of diminished quality of life for the patient after treatment. Wang’s study was designed to evaluate the swallow preservation [...]

2013-11-19T14:59:39-07:00November, 2013|Oral Cancer News|
Read More

Global trends in oral cancers

Source: www.dailyrx.com Author: staff It used to be that smoking and drinking alcohol were the biggest risk factors for cancers that develop in the mouth and throat. Those trends may be changing, according to a new study. That new study uncovered that cancers that appear in the throat right behind the mouth have increased, primarily in developed countries. The trend has been most prevalent in men under the age of 60, the researchers found. These increases, the authors suggested, may be linked to human papillomavirus (HPV), a sexually transmitted virus that’s associated with a number of cancers, including oral cancers. Anil K. Chaturvedi, PhD, of the National Cancer Institute, led this study that examined incidence trends for oropharyngeal (part of the throat behind the mouth) and oral cavity (mouth) cancers in 23 countries across four continents. The researchers examined the countries’ cancer registry data for the years 1983 to 2002. In the study’s introduction, the authors noted that oral cavity cancers (OCC) have declined recently in most parts of the world due to the declines in tobacco use. At the same time, oropharyngeal cancers (OPC) have risen over the past 20 years in some countries. OPC rates were compared to those of OCC and lung cancers to distinguish the potential role of HPV from smoking-related cancer trends. The researchers tracked specific OPC sites, including base of the tongue, tonsils, oropharynx and pharynx (throat). OCC sites included the tongue, gums, floor of the mouth, palate (roof of the mouth) and other [...]

2013-11-19T14:42:18-07:00November, 2013|Oral Cancer News|
Read More

Vitamin E may have adverse effect in head and neck cancer

Source: www.tele-management.ca According to a clinical trial, vitamin E supplements may increase the risk of a secondary tumor in those with head and neck cancer. Previous studies have suggested that a low dietary intake of antioxidants such as vitamins E and C might be linked to an increased risk of cancer. But there is no clear evidence that taking supplements decreases the risk.   Researchers in Quebec, Canada, report on a trial of vitamin E and beta-carotene, which is related to vitamin A, in patients with head and neck cancer. The patients took either supplements or placebo during radiation therapy and afterwards. The beta-carotene was stopped after a year, because a trial showed that those taking it who also smoked had an increased risk of getting lung cancer. The current trial showed that those on vitamin E were at increased risk of developing a second cancer while they were on the supplement, compared to those on placebo. But their risk was lower once the supplements had stopped. Overall, there was no difference between the two groups after eight years. These patients were at high risk anyway, so it is not really clear whether the results can be generalized to the whole population. There is clearly more research to be done before we can be clear whether vitamins can help in the fight against cancer.

2013-11-05T07:40:00-07:00November, 2013|Oral Cancer News|
Read More
© - The Oral Cancer Foundation - Head & Neck Cancer IRS 501(c)3 Charity - 3419 Via Lido #205, Newport Beach, CA 92663 | Disclaimer / Privacy Policy
Go to Top